iScience (Nov 2020)

c-Abl Inhibition Activates TFEB and Promotes Cellular Clearance in a Lysosomal Disorder

  • Pablo S. Contreras,
  • Pablo J. Tapia,
  • Lila González-Hódar,
  • Ivana Peluso,
  • Chiara Soldati,
  • Gennaro Napolitano,
  • Maria Matarese,
  • Macarena Las Heras,
  • Cristian Valls,
  • Alexis Martinez,
  • Elisa Balboa,
  • Juan Castro,
  • Nancy Leal,
  • Frances M. Platt,
  • Andrzej Sobota,
  • Dominic Winter,
  • Andrés D. Klein,
  • Diego L. Medina,
  • Andrea Ballabio,
  • Alejandra R. Alvarez,
  • Silvana Zanlungo

Journal volume & issue
Vol. 23, no. 11
p. 101691

Abstract

Read online

Summary: The transcription factor EB (TFEB) has emerged as a master regulator of lysosomal biogenesis, exocytosis, and autophagy, promoting the clearance of substrates stored in cells. c-Abl is a tyrosine kinase that participates in cellular signaling in physiological and pathophysiological conditions. In this study, we explored the connection between c-Abl and TFEB. Here, we show that under pharmacological and genetic c-Abl inhibition, TFEB translocates into the nucleus promoting the expression of its target genes independently of its well-known regulator, mammalian target of rapamycin complex 1. Active c-Abl induces TFEB phosphorylation on tyrosine and the inhibition of this kinase promotes lysosomal biogenesis, autophagy, and exocytosis. c-Abl inhibition in Niemann-Pick type C (NPC) models, a neurodegenerative disease characterized by cholesterol accumulation in lysosomes, promotes a cholesterol-lowering effect in a TFEB-dependent manner. Thus, c-Abl is a TFEB regulator that mediates its tyrosine phosphorylation, and the inhibition of c-Abl activates TFEB promoting cholesterol clearance in NPC models.

Keywords